Buy Abiraterone

Abiraterone

Abiraterone: Oncology Support Overview

Abiraterone, marketed as Abiraterone Acetate, is an oral oncology medication supplied in a 250 mg pill form. It belongs to the class of androgen biosynthesis inhibitors and is used primarily in the management of advanced prostate cancer. In Hong Kong, abiraterone is a prescription-only product regulated by the Department of Health.

How Abiraterone Works in the Body

Abiraterone acetate is a pro-drug that is rapidly converted to abiraterone after oral administration. The active molecule inhibits the enzyme CYP-17A1, which is essential for the production of androgen precursors in the adrenal glands, testes, and prostate tumor tissue. By blocking this enzyme, abiraterone markedly reduces circulating testosterone and other androgens that can stimulate prostate cancer growth.

Key pharmacologic points:

• Onset of action: Hormone suppression begins within a few days of the first dose.
• Duration: Continuous daily dosing maintains low androgen levels.
• Metabolism: Primarily hepatic via CYP3A4; metabolites are excreted in urine and feces.

Conditions Treated with Abiraterone

Abiraterone acetate is FDA- and EMA-approved for the treatment of:

• Metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received androgen-deprivation therapy (ADT).

In Hong Kong, the same indication is recognized by the local health authority. The drug is used in combination with continued ADT (e.g., luteinizing-hormone-releasing hormone agonists) to further suppress androgen-driven tumor progression.

Off-Label and Investigational Applications

Current peer-reviewed literature does not support widespread off-label use of abiraterone outside prostate cancer. Investigational studies have explored its role in other hormone-driven malignancies, but these remain experimental. Off-label use requires careful medical supervision and individualized risk assessment.

Who Should (Not) Use Abiraterone?

Absolute Contraindications

• Known hypersensitivity to abiraterone acetate or any of its excipients.
• Co-administration with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) that could markedly reduce drug exposure.

Relative Contraindications / Cautions

• Severe hepatic impairment (Child-Pugh C) - dose adjustment may be required.
• Moderate hepatic dysfunction (Child-Pugh B) - monitor liver enzymes closely.
• History of cardiovascular disease (e.g., uncontrolled hypertension, heart failure) - abiraterone can cause fluid retention and hypertension.
• Pregnancy or lactation - contraindicated; teratogenic risk is unknown, and the drug is not recommended for women of child-bearing potential.

Special Populations

• Elderly patients often have reduced renal or hepatic reserve; dose modifications should be guided by laboratory results.
• Patients with adrenal insufficiency should receive concurrent glucocorticoid supplementation (commonly prednisone 5 mg twice daily) to prevent mineralocorticoid excess.

When data are limited, clinicians typically apply the same precautions used for other CYP-17 inhibitors.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Hypertension - often manageable with antihypertensive agents.
• Fluid retention/edema - may require diuretics or dose adjustment.
• Hypokalemia - monitor serum potassium; supplement if needed.
• Fatigue - usually mild and improves over time.

Serious Adverse Events

• Hepatotoxicity - elevation of ALT/AST; discontinue if transaminases exceed three-times the upper limit of normal with bilirubin elevation.
• Severe hypertension or cardiac arrhythmias - requires immediate medical attention.
• Adrenal crisis - can occur if glucocorticoid supplementation is omitted; educate patients on stress-dose steroids.

Drug Interactions

• Major: Strong CYP3A4 inducers (e.g., rifampicin) can lower abiraterone plasma concentrations, reducing efficacy.
• Moderate: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase exposure; dose monitoring advised.
• Mineralocorticoid-related: Concurrent use with drugs that raise potassium (e.g., ACE inhibitors) may exacerbate hypokalemia.

Patients should provide a complete medication list-including over-the-counter products and herbal supplements-before starting therapy.

Food and Lifestyle Interactions

• Food: Take abiraterone on an empty stomach (at least 1 hour before or 2 hours after a meal) to maximize absorption.
• Alcohol: No specific restriction, but excessive intake can worsen liver toxicity.
• Driving: No impairment expected; however, severe fatigue or dizziness warrants caution.

Dosing and Administration Guidelines

• Standard regimen: Four 250 mg pills taken once daily (total 1000 mg), on an empty stomach, together with a glucocorticoid (commonly prednisone 5 mg twice daily). This dosing aligns with the approved label and is the most common clinical practice.
• Renal impairment: No dose adjustment is required for mild to moderate renal dysfunction, but monitor renal function periodically.
• Hepatic impairment: Use with caution; consider dose reduction or increased monitoring in moderate impairment.
• Missed dose: Take the missed dose as soon as remembered if within 12 hours; otherwise skip and resume the regular schedule. Do not double the next dose.
• Overdose: Symptoms may include severe nausea, vomiting, hypotension, and electrolyte disturbances. Seek emergency medical care; supportive care is the mainstay of treatment.
• Discontinuation: Abrupt cessation may precipitate adrenal insufficiency if glucocorticoid coverage is stopped simultaneously. Taper glucocorticoids under medical supervision.

Monitoring and Follow-Up

• Baseline labs: Liver function tests (ALT, AST, bilirubin), serum potassium, and blood pressure.
• Ongoing monitoring:
• Liver enzymes every 4-6 weeks for the first three months, then periodically.
• Serum potassium and blood pressure at each clinic visit.
• PSA (prostate-specific antigen) levels to assess oncologic response.
• Imaging: Periodic radiographic assessments (CT, bone scan) per oncology protocol.

Promptly report new or worsening hypertension, edema, or liver-related symptoms to the treating physician.

Storage and Handling

• Store the 250 mg pills at room temperature (20-25 °C), protected from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets after the printed expiration date.
• Dispose of unused medication according to local pharmacy or waste-management guidelines.

Medication-Specific Glossary

CYP-17A1

An enzyme (17α-hydroxylase/17,20-lyase) involved in the synthesis of androgens; abiraterone blocks its activity, reducing testosterone production.

Mineralocorticoid excess

A hormonal imbalance caused by increased aldosterone-like activity, leading to hypertension, hypokalemia, and fluid retention; mitigated by glucocorticoid co-therapy.

Glucocorticoid supplementation

Low-dose prednisone or equivalent given alongside abiraterone to prevent adrenal insufficiency and counteract mineralocorticoid effects.

Medical Disclaimer

This article provides educational information about abiraterone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.